REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Phosphorus Containing Other Than Solely As Part Of An Inorganic Ion In An Addition Salt Doai > Nitrogen Containing Hetero Ring > Polycylo Ring System Having A Ring Nitrogen In The System > Nonshared Hetero Atoms In At Least Two Rings Of The Polycyclo Ring System Nonshared Hetero Atoms In At Least Two Rings Of The Polycyclo Ring SystemNonshared Hetero Atoms In At Least Two Rings Of The Polycyclo Ring System patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027114 - Phosphonate analogs of antimetabolites The invention is related to phosphorus substituted antimetabolites, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. ... 02/01/07 - 20070027113 - Purine nucleoside phosphorylase inhibitory phosphonate compounds The invention is related to phosphorus substituted purine nucleoside phosphorylase inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds. ... 01/18/07 - 20070015732 - Adenosine receptor antagonists and methods of making and using the same In one embodiment, the invention features a compound of formula I: ... 01/18/07 - 20070015731 - 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands and the pharmaceutically acceptable salts thereof. The compounds are useful for the treatment of chemokine-mediated diseases such as COPD. ... 01/04/07 - 20070004680 - Compositions and methods for modulating gated ion channels The present invention relates to compositions and methods to modulate the activity of gated ion channels. ... 12/28/06 - 20060293284 - Novel acyclic nucleoside phosphonate derivatives, salts thereof and process for the preparation of the same The present invention relates to an acyclic nucleoside phosphonate derivative which is useful as an antiviral agent (particularly, against hepatitis B virus), pharmaceutically acceptable salts, stereoisomers, and a process for the preparation thereof. ... 12/28/06 - 20060293283 - Prodrugs of a2b adenosine receptor antagonists Disclosed are prodrugs of A2B adenosine receptor antagonists, and their use in treating mammals for various disease states. ... 11/09/06 - 20060252730 - Adenosine receptor antagonists and methods of making and using the same In one embodiment, the invention features a compound of formula I: ... 11/09/06 - 20060252729 - Nucleobase phosphonate analogs for antiviral treatment The present invention provides novel compounds with activity against infectious viruses. The compounds of the invention may inhibit retroviral reverse transcriptases and thus inhibit the replication of the virus. They are useful for treating human patients infected with a human retrovirus, such as human immunodeficiency virus (strains of HIV-1 or ... 11/02/06 - 20060247212 - Heterocyclic compounds having inhibitory activity against hiv integrase a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug. ... 10/19/06 - 20060234983 - Prodrugs of 2,4-pyrimidinediamine compounds and their uses The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications. ... 10/19/06 - 20060234982 - Compositions and methods for combination antiviral therapy The present invention relates to therapeutic combinations of [9-[R-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino]-phenoxyphosphinyl]methoxy]propyl]adenine (GS-7340) and (2R, 5S, cis)-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one (emtricitabine, (−)-cis FTC, Emtriva™ and their physiologically functional derivatives. The combinations may be useful in the treatment of HIV infections, including infections with HIV mutants bearing resistance to nucleoside and/or non-nucleoside inhibitors. The present invention is ... 09/21/06 - 20060211657 - Prodrugs of 2,4-pyrimidinediamine compounds and their uses The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications. ... 09/14/06 - 20060205693 - Antisense antiviral compounds and methods for treating a filovirus infection The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Filoviridae family, and in the treatment of a viral infection. The compounds and methods relate to the treatment of viral infections in mammals including primates by Ebola and Marburg ... 08/31/06 - 20060194767 - Novel agents for preventing and treating disorders involving modulation of the ryr receptors and salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated ... 08/10/06 - 20060178345 - Substituted alcohols useful in treatment of alzheimer's disease wherein X, R1, R2, R3, RN, R20 and RC are defined herein. The compounds are useful in the treatment or prevention of Alzheimer's disease and more specifically to compounds that are capable of inhibiting beta-secretase, an enzyme that cleaves amyloid precursor protein to produce amyloid beta peptide (A-beta), a major ... 08/03/06 - 20060172974 - Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine The instant disclosure provides crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, salts and solvates thereof. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form(s), as well of methods of using the crystalline form(s) in the treatment of HIV and/or AIDS, and methods for obtaining such crystalline form(s). ... 08/03/06 - 20060172973 - Diketo acids with nucleobase scaffolds: anti-hiv replication inhibitors targeted at hiv integrase A new class of diketo acids constructed on nucleobase scaffolds, designed as inhibitors of HIV replication through inhibition of HIV integrase, is described. These compounds are useful in the prevention or treatment of infection by HIV and in the treatment of AIDS and ARC, either as the compounds, or as ... 06/15/06 - 20060128669 - Heterocyclic compounds having inhibitory activity against hiv integrase a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug. ... 06/08/06 - 20060122154 - Thionucleoside derivatives as inhibitors of rna-dependent rna viral polymerase The present invention provides thionucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RNA viral infection. They are particularly useful as inhibitors of hepatitis C virus (HCV) NS5B ... 05/25/06 - 20060111324 - (+)-ttrans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl)methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof The present invention relates to (+)-trans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl)methyl nucleoside derivatives of the formula (1) which are useful as an antiviral agent (particularly, against hepatitis B virus), pharmaceutically acceptable saltss, hydrates, or solvates thereof, and processes for the preparation of stereoisomers of the compounds of the formula (1), and a composition ... 03/16/06 - 20060058266 - Chemically modified oligonucleotides This invention relates composition and methods for making and using chemically modified oligonucleotides agents for inhibiting gene expression. ... 03/16/06 - 20060058265 - Topical antiviral formulations The present invention relates to formulations of nucleotide reverse transcriptase inhibitors (NRTIs), preferably [2-(6-Amino-purin-9-yl)-1-methyl-ethoxymethyl]-phosphonic acid (tenofovir, PMPA), or a physiologically functional derivative thereof, suitable for topical application and their use in the prevention of HIV infections. ... 03/09/06 - 20060052346 - Nucleoside phosphonate derivatives useful in the treatment of hiv infections The present invention relates to a method of treating HIV infections by administering a nucleoside phosphonate derivative represented by formula (1). ... 03/09/06 - 20060052345 - Quinazolinone compounds as calcilytics Various calcilytic compounds and pharmaceutical compositions containing these compounds are disclosed. Calcilytic compounds are compounds capable of inhibiting calcium receptor activity. Techniques which can be used to obtain calcilytic compounds and uses of calcilyitc compounds as calcium receptor antagonists are also disclosed. ... 03/02/06 - 20060046981 - Anti-nonmelanoma carcinoma compounds, compositions, and methods of use thereof W5 is carbocycle or heterocycle wherein W5 is independently substituted with 0 to 3 R2 groups; and M2 is 0, 1 or 2; and pharmaceutically acceptable salts thereof. ... 02/09/06 - 20060030545 - Anti-proliferative compounds, compositions, and methods of use thereof W5 is carbocycle or heterocycle wherein W5 is independently substituted with 0 to 3 R2 groups; and M2 is 0, 1 or 2; or pharmaceutically acceptable salts thereof. ... 02/02/06 - 20060025384 - New crystal form of adefovir dipivoxil and its composition A new crystal form of adefovir dipivoxil {9-[2-[[bis[(neovaleroxy)-methoxy]phosphinyl]methoxy]ethyl]adenine} and its composition, and the method to prepare the crystal. ... 01/05/06 - 20060003968 - Azaindoles useful as inhibitors of rock and other protein kinases The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. ... 12/22/05 - 20050282782 - Lewis acid mediated synthesis of cyclic esters Methods for the synthesis of cyclic phosphonic acid diesters from 1,3-diols are described, whereby cyclic phosphonic acid diesters are produced by reacting a chiral 1,3-diol and an activated phosphonic acid in the presence of a Lewis acid. ... 12/15/05 - 20050277619 - Novel purine inhibitors of fructose-1,6-bisphosphatase Novel purine compounds of Formula 1, pharmaceutically acceptable prodrugs and salts thereof, and their use as fructose 1,6-bisphosphatase inhibitors. ... 11/24/05 - 20050261249 - Antisense composition and method for treating cancer A method and composition for of treating cancer, and in particular, for arresting the progression of a solid or primary cancer to a more invasive, metastatic state, are disclosed. The composition includes a substantially uncharged antisense compound (i) having a nuclease-resistant backbone, (ii) capable of uptake by target cancer cells ... 11/24/05 - 20050261248 - New-4-pyrrolopyrimidin-6-yl)benzenesulphonamide derivatives This invention is directed to selective antagonists of A2A and/or A2B adenosine receptors having the general formula (I); to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy. ... 11/24/05 - 20050261247 - Inhibition of jun kinase Disclosed herein are compositions and methods used to modulate a NH2-terminal Jun Kinase activity. These compositions and methods can be employed to regulate metabolic disorders associated with, for example, insulin such as diabetes. The reduction in NH2-terminal Jun Kinase activity can lead to the reduction in weight and improve insulin ... 10/27/05 - 20050239753 - Methods of inhibition of mmtv-like viruses The active metabolites of adefovir and tenofovir (PMEApp and PMPApp) are active against the MMTV RT. They are 25-fold more potent than 3TCppp, suggesting that tenofovir and adefovir may be effective at inhibiting the MMTV-like retroviruses, which may be the etiological agents involved in PBC and breast cancer. ... 10/27/05 - 20050239752 - Indole compounds useful for the treatment of cancer The present invention provides novel indole derivatives useful to inhibit cancer or sensitize cancer cells to chemotherapeutic agents, radiation or other anti-cancer treatments. ... 10/06/05 - 20050222090 - Anti-proliferative compounds, compositions, and methods of use thereof W5 is carbocycle or heterocycle wherein W5 is independently substituted with 0 to 3 R2 groups; and M2 is 0, 1 or 2; and pharmaceutically acceptable salts thereof. ... 09/15/05 - 20050203065 - Method of treating ischemia reperfusion injury using adenosine receptor antagonists Methods useful for preventing, limiting, or treating ischemia reperfusion injury in a mammal are disclosed. More particularly, this invention relates to administering A2b adenosine receptor antagonists to prevent, limit or treat ischemia reperfusion injury. ... 07/21/05 - 20050159392 - Prodrugs of phosphonate nucleotide analogues having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. ... 06/09/05 - 20050124585 - Prodrugs of phosphonate nucleotide analogues having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. ... 06/09/05 - 20050124584 - Prodrugs of phosphonate nucleotide analogues having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. ... 06/09/05 - 20050124583 - Prodrugs of phosphonate nucleotide analogues having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided. ... 06/09/05 - 20050124582 - 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purine antiviral agents R3 is selected from the group consisting of alkyl, alkenyl, alkynyl, and cycloalkyl, any of which may be branched or unbranched and optionally substituted with one or more members of the group consisting of hydroxy, halo, amino, acyl, cycloalkyl, heterocyclyl and aryl. ... ### FreshPatents.com Support |